CG Oncology, Inc. $CGON is Seven Fleet Capital Management LP’s Largest Position

Seven Fleet Capital Management LP lifted its holdings in shares of CG Oncology, Inc. (NASDAQ:CGON) by 24.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,886,236 shares of the company’s stock after buying an additional 371,085 shares during the quarter. CG Oncology makes up approximately 22.1% of Seven Fleet Capital Management LP’s investment portfolio, making the stock its largest position. Seven Fleet Capital Management LP’s holdings in CG Oncology were worth $134,017,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Fiduciary Financial Advisors purchased a new stake in CG Oncology in the 2nd quarter worth $28,000. NFSG Corp acquired a new position in CG Oncology during the first quarter worth $34,000. Comerica Bank lifted its holdings in CG Oncology by 100.4% during the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after purchasing an additional 515 shares in the last quarter. Fifth Third Bancorp purchased a new position in CG Oncology during the first quarter valued at $74,000. Finally, KBC Group NV acquired a new stake in shares of CG Oncology in the first quarter valued at about $78,000. Hedge funds and other institutional investors own 26.56% of the company’s stock.

Insider Transactions at CG Oncology

In other news, Director Leonard E. Post sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $70.00, for a total transaction of $350,000.00. Following the transaction, the director directly owned 5,000 shares in the company, valued at $350,000. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Brian Liu purchased 371,085 shares of the company’s stock in a transaction dated Thursday, June 25th. The stock was bought at an average price of $66.87 per share, with a total value of $24,814,453.95. Following the completion of the transaction, the director directly owned 1,886,236 shares of the company’s stock, valued at approximately $126,132,601.32. This represents a 24.49% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have sold a total of 37,129 shares of company stock worth $2,683,857 in the last ninety days. Insiders own 4.80% of the company’s stock.

Analysts Set New Price Targets

CGON has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and set a $100.00 target price on shares of CG Oncology in a research note on Wednesday, July 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of CG Oncology in a report on Friday, July 17th. Royal Bank Of Canada decreased their target price on CG Oncology from $81.00 to $79.00 and set an “outperform” rating on the stock in a research report on Friday, August 7th. Wolfe Research initiated coverage on CG Oncology in a research note on Tuesday, May 19th. They issued a “peer perform” rating on the stock. Finally, Wall Street Zen cut CG Oncology from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Eleven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $83.18.

CG Oncology Trading Up 0.5%

NASDAQ:CGON opened at $74.67 on Friday. The company has a market cap of $6.62 billion, a P/E ratio of -27.76 and a beta of 0.24. CG Oncology, Inc. has a twelve month low of $29.85 and a twelve month high of $80.97. The company’s 50-day moving average price is $73.63 and its 200-day moving average price is $67.25.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.24). The business had revenue of $1.16 million for the quarter, compared to analysts’ expectations of $0.36 million. CG Oncology had a negative net margin of 3,602.68% and a negative return on equity of 25.20%. On average, analysts expect that CG Oncology, Inc. will post -3.27 earnings per share for the current year.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.